Secondary hemophagocytic lymphohistiocytosis associated with adjuvant pembrolizumab therapy in a young patient with triple-negative breast cancer: a case report with literature review
Archives of Gynecology and Obstetrics · 03.07.2025 · 312 (5) · 1813-1820
DOI: 10.1007/s00404-025-08078-4 ↗Kurz gefasst
Fallbericht in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 03.07.2025. Verfasst von G L Olmes und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, 66421, Homburg, Germany. gregor.olmes@uks.eu. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes.
Abstract (Originalsprache)
Purpose
Secondary hemophagocytic lymphohistiocytosis (HLH) associated with pembrolizumab is a rare immune-related adverse event (irAE). It features a potential life-threatening status including fever and a hyperinflammatory reaction caused by natural killer cells, CD8 + cytotoxic T cells, and antigen-presenting cells leading to multiorgan failure. Secondary HLH is described for immune checkpoint inhibitor (ICI) therapy. Most descriptions refer to patients with melanoma or lung cancer. We report about a 32 year-old patient with secondary HLH associated with adjuvant pembrolizumab therapy according to the Keynote-522 protocol. It was successfully treated with prednisolone.
Methods
We performed a literature review in PubMed including the terms “HLH OR hemophagocytic lymphohistiocytosis AND breast cancer”. We found four other cases meeting the inclusion criteria (abstract available in English, breast cancer patient, HLH related to ICI therapy).
Results
Apart from the case report, the review featured main aspects about the diagnosis (HScore, histopathological assessment), onset of HLH, and medical treatment. The review indicated that secondary ICI induced HLH in breast cancer patients may be associated with complete response according to their tumor burden. Most cases are reported with an onset of secondary HLH within the neoadjuvant treatment phase and were treated analogously to the Keynote-522 protocol. Our case showed an onset almost 1 year after the initiation of pembrolizumab therapy.
Conclusion
Gyneco-oncologist should be aware of secondary HLH during pembrolizumab therapy and should assess patients with persistent fever using the HScore to diagnose secondary HLH early.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, 66421, Homburg, Germany. gregor.olmes@uks.eu.
- Department of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Medical Center, 66421, Homburg, Germany.
- Department for Oncology and Hematology, University Hospital Medical School, 66421, Homburg, Germany.
- Institute of General and Special Pathology, University Medical School of Saarland, 66421, Homburg, Saar, Germany.
ORCID-Profile: G L Olmes
Förderung
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Zitieren
APA
Olmes, G. L., Nigdelis, M. P., Hamoud, B. H., Solomayer, E. F., Bewarder, M., Bittenbring, J. T., Kranzhöfer, N., Thurner, L., Kim, Y. J., Seibold, A., & Doerk, M. (2025). Secondary hemophagocytic lymphohistiocytosis associated with adjuvant pembrolizumab therapy in a young patient with triple-negative breast cancer: a case report with literature review. Archives of Gynecology and Obstetrics, 312(5), 1813-1820. https://doi.org/10.1007/s00404-025-08078-4
Vancouver
Olmes GL, Nigdelis MP, Hamoud BH, Solomayer EF, Bewarder M, Bittenbring JT, et al. Secondary hemophagocytic lymphohistiocytosis associated with adjuvant pembrolizumab therapy in a young patient with triple-negative breast cancer: a case report with literature review. Archives of Gynecology and Obstetrics. 2025;312(5):1813-1820. doi:10.1007/s00404-025-08078-4
BibTeX
@article{Olmes2025,
author = {Olmes, G L and Nigdelis, M P and Hamoud, B Haj and Solomayer, E-F and Bewarder, M and Bittenbring, J T and Kranzhöfer, N and Thurner, L and Kim, Y-J and Seibold, A and Doerk, M},
title = {Secondary hemophagocytic lymphohistiocytosis associated with adjuvant pembrolizumab therapy in a young patient with triple-negative breast cancer: a case report with literature review},
journal = {Archives of Gynecology and Obstetrics},
year = {2025},
volume = {312},
number = {5},
pages = {1813--1820},
doi = {10.1007/s00404-025-08078-4}
}
EUVIMED